CHOLYSER

CHOLYSER™ is the trade name for cyclodextrin polymers developed by Renatus. CHOLYSER™ includes a range of soluble, cross-linked cyclodextrin polymers. Polymerization of cyclodextrins offers several advantages over cyclodextrin monomers, such as:

1. Increased solubilization of poorly water-soluble (hydrophobic) drugs or molecules

2. Improved stability of the cyclodextrin-guest molecule complexes

3. Reduced toxicity

4. Improved pharmacokinetic properties

 

These advantages make CHOLYSER™ cyclodextrin polymers versatile materials for various applications in pharmaceuticals, food science, and environmental remediation.​

​​​

A key feature of CHOLYSER™ cyclodextrin polymers is their significantly improved ability to solubilize cholesterol compared to leading commercial products, such as hydroxypropyl-modified β cyclodextrin (HPβCD). Importantly, CHOLYSER™ cyclodextrin polymers do not interact with cholesterol in cell membranes, minimizing non-selective cholesterol depletion and cyclodextrin-induced cytotoxicity.

​

Thanks to these unique properties, CHOLYSER™ cyclodextrin polymers are being developed as cholesterol-targeted therapeutics for diseases associated with dysregulated cholesterol homeostasis, including chronic kidney disease, Alzheimer's disease, metabolic dysfunction-associated steatohepatitis, and atherosclerosis.